Consensus Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse Other stock markets 04:00:22 2023-12-04 pm EST			Pre-market 07:13:13 am
29.28 ^USD	+1.28%		29.44	+0.56%

07:48am	Valneva: recruitment completed for VALOR trial	CF
06:29am	Pfizer, Valneva Conclude Enrollment in Late-stage Study of Lyme Disease Vaccine	MT

Evolution of the average Target Price on Pfizer, Inc.

Price target over the last 5 years

History : Analyst Recommendations

5763679f3e40fb.bZW5OUEr4V_RF2aghc1sO_s2OjmL_AU4CTv8Ko-IqSY.Ptnbbyp8pifnfiDWzKA-coxRUnG8vk9CYGqEXvvq2V8F8vVeLH3UMo5eKw~e40a430f02eadfedbd92552e67ebb4fa

Analyst Recommendations on Pfizer, Inc.

PFIZER INC : UBS sticks Neutral	Dec. 01	ZD
PFIZER INC : JP Morgan remains Neutral	Dec. 01	ZD
PFIZER INC : JP Morgan sticks Neutral	Nov. 27	ZD
Barclays Adjusts Price Target on Pfizer to $34 From $35, Maintains Equal-Weight Rating	Nov. 01	MT
Morgan Stanley Adjusts Price Target on Pfizer to $37 From $39, Keeps Equalweight Rating	Nov. 01	MT
PFIZER INC : UBS reaffirms its Neutral rating	Oct. 31	ZD
PFIZER INC : UBS remains Neutral	Oct. 31	ZD
PFIZER INC : JP Morgan reiterates its Neutral rating	Oct. 31	ZD
PFIZER INC : Jefferies maintains a Buy rating	Oct. 30	ZD
PFIZER INC : UBS Upgrades to Neutral	Oct. 20	ZD
UBS Adjusts Pfizer Price Target to $34 From $36, Maintains Neutral Rating	Oct. 20	MT
PFIZER INC : UBS remains Neutral	Oct. 18	ZD
Morgan Stanley Trims Price Target on Pfizer to $39 From $40, Maintains Equalweight Rating	Oct. 17	MT
PFIZER INC : JP Morgan gives a Neutral rating	Oct. 16	ZD
PFIZER INC : UBS sticks Neutral	Oct. 16	ZD
Jefferies Upgrades Pfizer to Buy From Hold, Adjusts Price Target to $39 From $38	Oct. 16	MT
Wells Fargo Lowers Price Target on Pfizer to $35 From $39, Maintains Equalweight Rating	Oct. 16	MT
ANALYST RECOMMENDATIONS : Autozone, Boeing, Pfizer, Rio Tinto, United Health...	Oct. 16
PFIZER INC : Upgraded to Buy by Jefferies	Oct. 16	ZD
JPMorgan Cuts Price Target on Pfizer to $36 From $39, Maintains Neutral Rating	Oct. 06	MT
ANALYST RECOMMENDATIONS : Amgen, Best Buy, Comcast, Fedex, Mosaic...	Oct. 02
ANALYST RECOMMENDATIONS : Microsoft, Adobe, Salesforce, Pfizer...	Sep. 15
UBS Adjusts Pfizer Price Target to $36 From $38, Maintains Neutral Rating	Aug. 02	MT
Jefferies Adjusts Price Target on Pfizer to $38 From $40, Maintains Hold Rating	Aug. 02	MT
Morgan Stanley Adjusts Price Target on Pfizer to $40 From $42, Maintains Equalweight Rating	Aug. 02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.28USD

Average target price

40.41USD

Spread / Average Target

+38.02%

High Price Target

75USD

Spread / Highest target

+156.15%

Low Price Target

32USD

Spread / Lowest Target

+9.29%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pfizer, Inc.

JPMORGAN	Chris Schott
UBS	Trung Huynh
Barclays
Morgan Stanley
JEFFERIES	Akash Tewari
Jefferies & Co.
Wells Fargo Securities
JPMorgan Chase
BMO Capital
SVB Securities LLC
Credit Suisse
Goldman Sachs
Truist Securities
HSBC
Berenberg Bank
BERENBERG	Kerry Holford
Daiwa Securities
BofA Securities
Atlantic Equities
Citigroup
Mizuho Securities
Atlantic Securities
SVB Leerink
Independent Research
Cantor Fitzgerald
RBC
RBC Capital Markets
J.P. Morgan Chase
DZ Bank

Ratings for Pfizer, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar